$ICCM

IceCure Medical (ICCM) presented 12-month clinical data for its ProSense® breast cancer cryoablation system at EUSOBI, showing a 97.5% response rate in 40 patients. The company hosted workshops and scientific sessions, highlighting strong physician engagement and growing interest in the minimally invasive treatment.

IceCure Medical (ICCM) added Legacy Health in Portland, OR, as a new U.S. clinical site for its ChoICE Study, evaluating ProSense® cryoablation for low-risk breast cancer. The study, approved by the FDA, aims to enroll 400 patients across 30 sites. Dr. Nathalie Johnson will lead the site's participation. IceCure's ProSense® is the only FDA-cleared device for this treatment in specific patients.

IceCure Medical Ltd. (ICCM) shares surged over 200% on Wednesday due to increased adoption of its ProSense system for breast cancer treatment. The company reported a 70% increase in U.S. commercial installations since FDA approval in October 2025. CEO Eyal Shamir cited growing physician interest and clinical acceptance. The stock is on track for its best day since August 2021. All three analysts covering ICCM rate it 'Buy' or higher, with an average price target of $44.50, implying a potential u

IceCure Medical (ICCM) received regulatory approval from China's NMPA for its ProSense cryoablation system, expanding its global market. The device, already cleared in the U.S. and Europe, is used to treat tumors in breast, kidney, bone, and lung. The approval was supported by clinical data, and the company plans to accelerate commercialization in China. ICCM's stock is up 1.42% to $2.14.

IceCure Medical (ICCM) signed an exclusive distribution agreement with Scovas Medical for ProSense® cryoablation systems in the Netherlands. The deal aims to expand ProSense® commercialization in a market with growing interest in minimally invasive cancer treatments. The THERMAC trial, in Phase III, supports cryoablation's potential for early-stage breast cancer treatment, with a 94% success rate.

IceCure Medical (ICCM) received IRB approval from West Cancer Center for its ChoICE study on ProSense® cryoablation for low-risk breast cancer. The study, expected to enroll patients soon, aims to gather real-world data on the treatment. ProSense® is FDA-approved for women 70+ with low-risk tumors. The study will involve 30 sites and 400 patients, expanding access to cryoablation.

IceCure Medical (ICCM) reported $1.8M in H1 2026 revenue, up 45% YoY. U.S. revenue grew 64% post-FDA clearance. Gross profit rose 57% to $548K, but net loss widened to $8.8M. Cash increased to $12M after $8.5M Q2 financing. Management highlighted growth in system and disposable probe sales, U.S. expansion, and the CHOICE study.

IceCure Medical (NASDAQ: ICCM) said two peer-reviewed publications support cryoablation for breast cancer de-escalation. The first cites FDA marketing authorization for ProSense and inclusion in updated ASBrS guidelines, referencing ICE3 five-year results with a 3.1% IBTR rate. The second discusses cryoablation for axillary lymph node metastases.

IceCure Medical (ICCM) reported six-month results ended June 30, 2026. Revenue rose 45% year over year to $1.8 million from $1.24 million. Gross profit increased to $548,000 from $349,000, helped by higher ProSense system and disposable probe sales. Cash was $12.0 million. The company said U.S. footprint grew 70% and it is advancing its CHoICE post-marketing study.

IceCure Medical reported Q2 2026 revenue up about 45%, driven by higher system sales and disposable probe use. Gross margin rose to 30% despite FX headwinds. U.S. footprint grew about 70% after FDA clearance. Management expects first CHOICE study patient enrollment in 3 to 4 weeks and 80 patients by March 2027. Cash was about $12M after a Q2 financing raising about $8.5M gross.